G
Gad Getz
Researcher at Broad Institute
Publications - 627
Citations - 309042
Gad Getz is an academic researcher from Broad Institute. The author has contributed to research in topics: Cancer & Biology. The author has an hindex of 189, co-authored 520 publications receiving 247560 citations. Previous affiliations of Gad Getz include University of Colorado Denver & University of California, San Diego.
Papers
More filters
Posted ContentDOI
A comprehensive analysis of RNA sequences reveals macroscopic somatic clonal expansion across normal tissues
Keren Yizhak,François Aguet,Jaegil Kim,Julian M. Hess,K Kübler,Jonna Grimsby,Ruslana Frazer,Hailei Zhang,Nicholas J. Haradhvala,Daniel Rosebrock,Dimitri Livitz,Xiao Li,Eila Arich-Landkof,Noam Shoresh,Chip Stewart,Segrè Av,Philip A. Branton,Paz Polak,Kristin G. Ardlie,Gad Getz +19 more
TL;DR: This study is the first to analyze a large number of samples across multiple normal tissues, identifying clones with genomic aberrations observed in cancer, and finds that mutation burden is associated with both the age of the individual and tissue proliferation rate.
Journal ArticleDOI
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness.
Yize Li,Tung-Shing M. Lih,Saravana M. Dhanasekaran,Rahul Mannan,Lijun Chen,Marcin Cieslik,Yige Wu,Rita Jui-Hsien Lu,David J. Clark,Iga Kołodziejczak,Runyu Hong,Siqi Chen,Yanyan Zhao,Seema Rani Rajni Chugh,Wagma Caravan,Nataly Naser Al Deen,Noshad Hosseini,Chelsea J. Newton,Karsten Krug,Yuanwei Xu,Kyung-Cho Cho,Yi-Kang Hu,Yuping Zhang,Chandan Kumar-Sinha,Weiping Ma,Anna Calinawan,Matthew A. Wyczalkowski,Michael C. Wendl,Yuefan Wang,Shenghao Guo,Cissy Zhang,Anne Le,Aniket Dagar,Alex Hopkins,Han Wool Cho,Felipe da Veiga Leprevost,Xiaojun Jing,Guo Ci Teo,Wenke Liu,Melissa A. Reimers,Russell K. Pachynski,Alexander J. Lazar,Arul M. Chinnaiyan,Brian A. Van Tine,Bing Zhang,Karin D. Rodland,Gad Getz,D. R. Mani,Pei Wang,Feng Chen,Galen Hostetter,Mathangi Thiagarajan,W. Marston Linehan,David Fenyö,Scott D. Jewell,Gilbert S. Omenn,Rohit Mehra,Maciej Wiznerowicz,Ana I. Robles,Mehdi Mesri,Tara Hiltke,Eunkyung An,Henry J Quintero Rodríguez,Daniel W. Chan,Christopher J. Ricketts,Alexey I. Nesvizhskii,Hui Zhang,Li Ding,Alicia Francis,Amanda G. Paulovich,Andrzej Antczak,Anthony Green,Antonio Colaprico,A. Ari Hakimi,Barbara L. Pruetz,Barbara Hindenach,Birendra Kumar Yadav,Boris Reva,Brenda Fevrier-Sullivan,Brian J. Druker,Cezary Szczylik,Charles A. Goldthwaite,Chet Birger,Corbin D. Jones,Daniel C. Rohrer,Darlene Tansil,David Chesla,David I. Heiman,Elizabeth R. Duffy,Erin Schadt,Francesca Petralia,Gabriel Bromiński,Gabriela Quiroga-Garza,George S. Wilson,Ginny Li,Grace Zhao,Yi-Jia Hsiao,James J. Hsieh,Jan Lubinski,Jasmin H. Bavarva,Jasmine Jiawei Huang,Jason Hafron,Jennifer M. Eschbacher,Jennifer Hon,Jesse Francis,John Freymann,Josh N. Vo,Joshua M. Wang,Justin Kirby,Kakhaber Zaalishvili,Karen A. Ketchum,Katherine A. Hoadley,Ki Sung Um,Liqun Qi,Marcin J. Domagalski,Matthew F. Tobin,Maureen Dyer,Meenakshi Anurag,Melissa Borucki,Michael A. Gillette,Michael J. Birrer,Michael Ittmann,Michael H.A. Roehrl,Michael Schnaubelt,Michael V. Smith,Mina M. Fam,Nancy Roche,Negin Vatanian,Nicollette S. Maunganidze,Olga Potapova,Oxana Paklina,Pamela VanderKolk,Patricia Castro,Paweł Murawa,Pushpa Hariharan,Qin Li,Qing Kay Li,Rajiv Dhir,Ratna R. Thangudu,Rebecca Montgomery,Richard D. Smith,Sailaja Mareedu,Samuel H. Payne,Sandra Cerda,Sandra Cottingham,Sarah Haynes,Shankha Satpathy,Shannon Richey,Shilpi Singh,Shirley Tsang,Shuang Cai,Song Cao,Stacey Gabriel,Steven A. Carr,Tao Li,Thomas Bauer,Toan Thuy Le,Xi Shan Chen,Xu Zhang,Yvonne Shutack,Zhenyu Zhang +160 more
TL;DR: In this article , integrative histopathologic, proteogenomic, and metabolomic analyses were performed on 305 ccRCC tumor segments and 166 paired adjacent normal tissues from 213 cases.
Journal ArticleDOI
Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
Jun Tian,Jonathan H. Chen,Sherry Chao,Karin Pelka,Marios Giannakis,Julian M. Hess,Kelly P. Burke,Vjola Jorgji,Princy Sindurakar,Jonathan Braverman,Arnav Mehta,Tomonori Oka,Mei Huang,David J. Lieb,Maxwell Spurrell,Jill N. Allen,Thomas A. Abrams,Jeffrey W. Clark,Andrea C. Enzinger,Peter C. Enzinger,Samuel J. Klempner,Nadine Jackson McCleary,Jeffrey A. Meyerhardt,David P. Ryan,Matthew B. Yurgelun,Katie Kanter,Emily E. Van Seventer,Islam Baiev,Gary Chi,Joy X. Jarnagin,William B. Bradford,Edmond Wong,Alexa G. Michel,Isobel J Fetter,Giulia Siravegna,Angelo J. Gemma,Arlene H. Sharpe,Shadmehr Demehri,Rebecca J. Leary,Catarina D. Campbell,Omer H. Yilmaz,Gad Getz,Aparna Raj Parikh,Nir Hacohen,Ryan B. Corcoran +44 more
TL;DR: This article performed a single-arm phase 2 clinical trial of combined PD-1, BRAF and MEK inhibition with sparatlizumab (PDR001), dabrafenib and trametinib in 37 patients with colorectal cancer.
Journal ArticleDOI
Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation
Rafael Bejar,Kristen E. Stevenson,Petar Stojanov,J. Eric Zaneveld,Michal Bar-Natan,Bennett Caughey,Hui Wang,Guillermo Garcia-Manero,Hagop M. Kantarjian,Corey Cutler,Jerome Ritz,Kristian Cibulskis,Gad Getz,David P. Steensma,Richard Stone,Rui Chen,Donna Neuberg,Benjamin L. Ebert +17 more
TL;DR: Gene mutations detected in over 200 MDS patients prior to treatment with hypomethylating agents and prior to undergoing stem cell transplantation are reported on to report a higher prognostic profile than previously reported.
Journal Article
Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution
Siddha Kasar,Jintaek Kim,Reina Improgo,Grace Tiao,Paz Polak,Nicholas J. Haradhvala,Michael S. Lawrence,Adam Kiezun,Stacey M. Fernandes,Samira Bahl,Carrie Sougnez,S. Gabriel,Hye-Yeong Kim,Gad Getz,Jennifer R. Brown,Eric S. Lander +15 more
TL;DR: This article performed whole-genome sequencing on a cohort of patients enriched with these cytogenetic characteristics and found that mutations in known CLL drivers are seen in only 33% of the patients, and associated with normal cytogenetics and unmutated IGHV.